A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects
- PMID: 1977781
A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects
Abstract
We objectively tested the relative antihistaminic effects of cetirizine, 10 mg; terfenadine, 120 mg; terfenadine, 60 mg; loratadine, 10 mg; astemizole, 10 mg; chlorpheniramine, 4 mg; and placebo in healthy, male volunteers, mean age 25 +/- 4 years, and mean weight, 73 +/- 9 kg. The wheal areas and flare areas produced by epicutaneous tests with histamine phosphate, 1 mg/ml, before ingestion of the H1-receptor antagonist or placebo, and afterward, at 0.3 and 0.7 hours, then hourly from 1 to 12 hours and at 24 hours, were traced at 10 minutes and measured with an IBM-PC digitizer and stereometric software. In this experimental model, the H1-receptor antagonists differed significantly with regard to time of onset of action, amount of suppression of the histamine-induced wheal and flare, and duration of action. The rank order was, from most effective to least effective, cetirizine, 10 mg; terfenadine, 120 mg; terfenadine, 60 mg; loratadine, 10 mg; astemizole, 10 mg; chlorpheniramine, 4 mg; and placebo.
Similar articles
-
Treatment of urticaria and angioedema: low-sedating H1-type antihistamines.J Am Acad Dermatol. 1991 Jun;24(6 Pt 2):1084-7. doi: 10.1016/0190-9622(91)70161-t. J Am Acad Dermatol. 1991. PMID: 1677011
-
Recent advances in H1-receptor antagonist treatment.J Allergy Clin Immunol. 1990 Dec;86(6 Pt 2):995-9. doi: 10.1016/s0091-6749(05)80242-8. J Allergy Clin Immunol. 1990. PMID: 1979802 Review.
-
A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects.Allergy. 1999 Jul;54(7):700-7. doi: 10.1034/j.1398-9995.1999.00032.x. Allergy. 1999. PMID: 10442525 Clinical Trial.
-
H1-receptor antagonist treatment of seasonal allergic rhinitis.J Allergy Clin Immunol. 1990 Dec;86(6 Pt 2):1000-3. doi: 10.1016/s0091-6749(05)80243-x. J Allergy Clin Immunol. 1990. PMID: 1979793 Review.
-
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.Ann Allergy Asthma Immunol. 2002 Feb;88(2):190-7. doi: 10.1016/S1081-1206(10)61995-3. Ann Allergy Asthma Immunol. 2002. PMID: 11868924 Clinical Trial.
Cited by
-
Evidence-based treatment of allergic rhinitis.Curr Allergy Asthma Rep. 2001 May;1(3):218-26. doi: 10.1007/s11882-001-0008-4. Curr Allergy Asthma Rep. 2001. PMID: 11892039 Review.
-
Cetirizine. An updated review of its pharmacological properties and therapeutic efficacy.Clin Rev Allergy. 1993 Spring;11(1):65-88. doi: 10.1007/BF02802294. Clin Rev Allergy. 1993. PMID: 8319162 Review. No abstract available.
-
Cetirizine: a review of its use in allergic disorders.Drugs. 2004;64(5):523-61. doi: 10.2165/00003495-200464050-00008. Drugs. 2004. PMID: 14977391
-
New insights into the second generation antihistamines.Drugs. 2001;61(2):207-36. doi: 10.2165/00003495-200161020-00006. Drugs. 2001. PMID: 11270939 Review.
-
Design of a suitable formulation of FK613, a novel antiallergic agent, based on its pharmacokinetic and pharmacodynamic properties in healthy subjects.Eur J Clin Pharmacol. 1996;49(4):279-84. doi: 10.1007/BF00226328. Eur J Clin Pharmacol. 1996. PMID: 8857073 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical